NCT04194216

Antibiotic Prophylaxis in Rhinoplasty

Comparison of Outcomes in Rhinoplasty With the Use of Intraoperative Versus Postoperative Antibiotics

• Status: Enrolling By Invitation
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 864 (estimated)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study compares the efficacy of a single intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides), alone versus both intra-operative (intravenous) dose of "cephalexin" (first generation cephalosporin) or "clindamycin" (lincosamides) and postoperative oral dose of "cephalexin" or "clindamycin" use in nasal surgery.

Detailed description

The study will consist of 2 treatment arms: Treatment arm A: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg. Treatment arm B: Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg every 4 hours or "clindamycin" 150mg every 6 hours, for a duration of three days.

Conditions

• Nasal Obstruction
• Nasal Surgical Procedures

Interventions

Type	Name	Description
DRUG	Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg.	Treatment Arm A
DRUG	Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days	Treatment Arm B

Timeline

• Start date: 2020-05-20
• Primary completion: 2026-12-20
• Completion: 2027-04-20
• First posted: 2019-12-11
• Last updated: 2024-12-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study